Carbohydrate-based Antiparasiti Glycomedicine Development

Carbohydrate-based Antiparasiti Glycomedicine Development

With the advanced carbohydrate-based glycomedicine development platform, we are able to provide customers with strong support for glycomedicine development. CD BioGlyco has abundant experience in carbohydrate-based antiparasiti glycomedicine development services. We expect to become customers' research assistants in the field of glycobiology and glycochemistry.

Carbohydrate-based Antiparasiti Glycomedicines

Parasitic infections are among the most prevalent and severe diseases in humans and other mammals. Half of the world's population, especially those in developing countries, are at risk of the most notorious parasitic diseases (i.e., malaria, leishmaniasis and trypanosomiasis). Although a wide variety of antiparasitic drugs are available for treating malaria, reinfection and drug resistance have been major issues, notably in the case of chloroquine.

Carbohydrates are abundantly present on the surface of parasites and play a key role in host-parasite interactions. Unique carbohydrate antigens characterize multiple developmental stages and tend to be immunoreactive for both protozoan and helminth parasites. Adding to the appeal of carbohydrate antigens is the ongoing, systematic characterization of parasite glycobiology regarding their structure, function and biosynthesis. As a result, producing carbohydrate-based antiparasiti glycomedicines is decisively the ultimate goal.

Fig.1 Aminoglycoside antibiotics antiparasitic drugs.Fig.1 Aminoglycoside antibiotics antiparasitic drugs. (Cao, et al., 2022)

Carbohydrate-based Antiparasiti Glycomedicines Development Services

As a leading resource provider in the glycobiology field, CD BioGlyco has various systematic services for the development of carbohydrate-based antiparasiti glycomedicines. CD BioGlyco offers services for the unique and abundant glycosylphosphatidylinositol (GPI) modifications rendering it a good target of the malaria parasite P. falciparum for carbohydrate-based antiparasiti development. The service for isolation of P. falciparum GPI and deacylation by enzymatic or chemical means renders the resulting non-toxic carbohydrate is available. We are able to help customs conjugate the antigen (the hapten) to an immunogenic carrier protein and chemically synthesize the GPI glycan.

A widely used carrier protein is keyhole limpet haemocyanin (KLH), which is potently immunogenic and displays free lysinederived amino groups that are available for conjugation. In addition, we provide services for precise carbohydrate structure determination and methods for large-scale synthesis of carbohydrate-based antiparasiti development. Importantly, screening and evaluation services of antiparasitic and anticancer activities can be provided.

Advantages of Us

  • Cutting-edge technology and professional research team.
  • Update methods according to international development.
  • Efficient, fast and practical service.
  • Extensive experience in the field of glycomedicine development.

With a first-class experimental platform and professional research teams, CD BioGlyco is committed to ensuring that every service provides the highest level of satisfaction. Our professional research teams provide customers with high-quality carbohydrate-based antiparasiti glycomedicines development services according to their needs. If you are interested in our services, please contact us to obtain more information.


  1. Cao, X.; et al. Carbohydrate-based drugs launched during 2000-2021. Acta Pharmaceutica Sinica B. 2022.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.